Ken Griffin Immunic, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.08 - $1.95 $4,968 - $8,970	-4,600 Reduced 97.87%	100 $0
Q2 2024 Aug 14, 2024	BUY	$0.98 - $1.44 $4,018 - $5,904	4,100 Added 683.33%	4,700 $5,000
Q1 2024 May 15, 2024	SELL	$1.14 - $1.53 $5,813 - $7,803	-5,100 Reduced 89.47%	600 $0
Q4 2023 Feb 14, 2024	SELL	$0.97 - $1.6 $3,977 - $6,560	-4,100 Reduced 41.84%	5,700 $8,000
Q3 2023 Nov 14, 2023	SELL	$1.35 - $2.87 $77,625 - $165,025	-57,500 Reduced 85.44%	9,800 $14,000
Q2 2023 Aug 14, 2023	BUY	$1.33 - $2.51 $85,918 - $162,146	64,600 Added 2392.59%	67,300 $168,000
Q1 2023 May 15, 2023	SELL	$1.35 - $2.87 $119,205 - $253,421	-88,300 Reduced 97.03%	2,700 $4,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $677 - $6,480	600 Added 0.66%	91,000 $127,000
Q3 2022 Nov 14, 2022	SELL	$3.0 - $5.49 $341,100 - $624,213	-113,700 Reduced 55.71%	90,400 $286,000

56.2M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $35.5M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.